向日葵9月8日停牌，筹划收购兮璞材料控股权及贝得药业40%股权

Group 1 - The company Sunflower plans to acquire controlling stakes in Xi Pu Materials and 40% of Bei De Pharmaceutical, which is expected to constitute a major asset restructuring [2][5] - The stock of Sunflower was suspended from trading starting September 8, following a significant price increase of 11.96% on September 5, leading to a market capitalization of 6.385 billion [2][5] - The valuation of Xi Pu Materials and Bei De Pharmaceutical has not been finalized, but preliminary assessments indicate that the transaction will meet the criteria for a major asset restructuring as per regulations [5][9] Group 2 - Sunflower has signed a letter of intent with the major shareholder of Xi Pu Materials, Shanghai Xi Pu Technology, to acquire its controlling stake through share issuance and/or cash payment [8] - The company also signed a letter of intent with Shaoxing Sunflower Investment to acquire 40% of Bei De Pharmaceutical's shares, which will make Bei De a wholly-owned subsidiary if the transaction is completed [9][12] - The current focus of Sunflower is on the pharmaceutical sector, with its main products including anti-infection drugs, cardiovascular drugs, and digestive system drugs [13] Group 3 - In the first half of 2025, Sunflower reported a revenue decline of 8.33% to 144.42 million, and a net profit drop of 35.68% to 1.16 million [14][15] - The decline in performance is attributed to reduced sales profits, changes in period expenses, and increased inventory impairment provisions [15] - The market demand for the company's formulation drugs has decreased, particularly affecting the sales of anti-infection products like azithromycin [15]